Unstable angina and non-ST elevation myocardial infarction

Acute Pharmacological Management of Unstable Angina and Non-ST Elevation Myocardial Infarction... 

Glycoprotein llb/llla inhibitors in unstable angina and non-ST elevation myocardial infarction... 

Morrow DA, Cannon CR Rifai N, et al. Ability of minor elevations of troponin I and troponin T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction. J Am Med Assoc 2001 286 2405-2412. 

Holper EM, Antman EM, McCabe CH et al. A simple, readily available method for risk stratification of patient with unstable angina and non-ST elevation myocardial infarction. Am J Cardiol 2001 87 1008. 

Cannon CP, Weintraub WS, Demopoulos L A, et at. Comparison of early invasive versus early conservative strategies in patients with unstable angina and non-ST elevation myocardial infarction treated with early glycoprotein Ilb/IIIa inhibition. N Engl J Med 2001 344(25) 1879-87. 

For the Phase 1 study, sii le doses of Serp-1 protein were infused in normal volunteers as mandated by the FDA. This was the first trial in man with a new class of virus-derived native protein therapeutic No changes in cardiac, renal or hepatic function, as well as no chaises in clotting parameters were detected in this study. This Phase 1 safety study demonstrated that Serp-1 infusion was safe with no adverse events detected or reported. A Phase Ila study is currently ongoii in which the effects of a Serp-1 infusion is given for three days startup immediately after balloon ai oplasty and stent implant in patients with acute unstable angina and non-ST elevation myocardial infarction (NSTEMl). This trial is still ongoing at 7 sites in Canada and the US. The... 

---